News | November 17, 2010

Bridge-to-Transplant Trial Shows 92 Percent Success

November 17, 2010 – Data from the ADVANCE bridge-to-heart-transplant study showed that 92 percent of patients were either alive on the implanted device, had a heart transplant or explanted for recovery. The study looked at the HeartWare Ventricular Assist System at 180 days.

Between August 2008 and February 2010, 140 patients at 30 U.S. hospitals received the device, which has been approved by the U.S. Food and Drug Administration (FDA) as an IDE.

"Implantation of the investigational device was associated with a high probability of success at 180 days. We observed marked improvement in two heart failure specific and two generalized quality of life measures from initial patient baseline," said Keith Aaronson, M.D. M.S., co-principal investigator of the study. "HeartWare patients were able to walk 113 meters farther in six minutes when tested three months after surgery and patient assessment of their own quality of life more than doubled. The adverse event profile from the trial data appears to be favorable, with observed bleeding, infection and ventricular arrhythmia rates at relatively low levels."

"Investigators found that the small device size, with implantation in the pericardial space adjacent to the heart, reduced the complexity of the implant procedure," said Mark Slaughter, M.D., co-principal investigator, professor and chief in the division of thoracic and cardiovascular surgery, and director of the mechanical assist device and heart transplant program at the University of Louisville in Louisville, Ky. "These device attributes and overall performance help account for the acceleration of enrollment rate we observed during the ADVANCE study."

The system is a small full-output circulatory support device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HVAD pump weighs approximately five ounces and displaces a volume of approximately 50 milliliters.

For additional information: www.heartware.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init